
We conducted a phase I trial to examine the zzso tolerated dose zzso of the oral zzso inhibitor zzso zzso in combination with zzso and concurrent zzso in patients with zzso and to gather preliminary data for zzso The study was conducted in patients with newly diagnosed zzso after surgical zzso Patients were treated with standard zzso zzso zzso to the gross tumor zzso zzso (75 zzso zzso together with daily oral zzso starting zzso days prior to zzso continuing for the duration of zzso for 6 zzso zzso zzso zzso was resumed 4 weeks after completion of zzso Two dose levels of zzso were zzso 625 zzso twice daily zzso and 1,250 zzso bid in a cohort escalation zzso A total of 21 patients were zzso At the maximum tolerated dose, 18 subjects were enrolled to further evaluate toxicity and for preliminary estimate of efficacy for further phase II zzso No zzso toxicity was noted at 625 zzso zzso At 1,250 zzso bid, 3 zzso episodes of zzso were noted and one zzso episode of zzso The zzso for this study was 1,250 zzso zzso zzso zzso zzso zzso concurrent with zzso and zzso is tolerated in most patients with zzso At the 1,250 zzso bid dose level, patients should be monitored for zzso and zzso side zzso 

